<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983512</url>
  </required_header>
  <id_info>
    <org_study_id>TWTPV-E1001</org_study_id>
    <nct_id>NCT03983512</nct_id>
  </id_info>
  <brief_title>PULSTA Transcatheter Pulmonary Valve Pre-Approval Study</brief_title>
  <official_title>The PULSTA Transcatheter Pulmonary Valve (TPV) Pre-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taewoong Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Factory CRO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Taewoong Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of the PULSTA
      Transcatheter Pulmonary Valve (TPV) System for the treatment of congenital or acquired
      pulmonary valve stenosis and/or regurgitation who require pulmonary valve replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PULSTA TPV is a self-expandable valve with flared-ends to adapt to the larger native
      right ventricular outflow tract (RVOT) and is using a relatively low profile delivery
      catheter from knitted nitinol wire backbone and trileaflets made from treated porcine
      pericardial tissue, and a delivery system, which provides access to the right ventricular
      outflow tract through blood vessels. Consecutive subject data should be collected at
      discharge, 1, 6 months, and 1-5 years post PULSTA TPV implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural/Device related serious adverse events at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic functional improvement at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Hemodynamic functional improvement is a composite of mean RVOT gradient ≤30 mmHg by continuous wave Doppler and a pulmonary regurgitant fraction &lt;20% by cardiac magnetic resonance (MR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>7 days</time_frame>
    <description>Procedural success is defined as the TPV implant within desired position, Right ventricle-Pulmonary artery (RV-PA) peak systolic pressure gradient &lt;35mmHg by catheter, less mild pulmonary regurgitation by angiography, and freedom from explantation of the TPV at 24 hours post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Function</measure>
    <time_frame>5 years</time_frame>
    <description>Hemodynamic function will be assessed including peak RVOT pressure gradient, mean RVOT pressure gradient, right ventricle (RV) end-diastolic volume index by echocardiography or cardiac MR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Regurgitant Fraction</measure>
    <time_frame>6months</time_frame>
    <description>Pulmonary regurgitant fraction (PRF) will be assessed via cardiac MRI at 6 months after the PULSTA TPV implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Pulmonary Regurgitation</measure>
    <time_frame>5 years</time_frame>
    <description>Severity of pulmonary regurgitation will be assessed via Doppler echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional classification</measure>
    <time_frame>5 years</time_frame>
    <description>Clinical outcome will be assessed as per the New York Heart Association (NYHA) functional classification t all follow-up visits and will be compared to baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter reintervention on TPV</measure>
    <time_frame>5 years</time_frame>
    <description>Catheter re-intervention on PULSTA TPV is defined as any interventional catheter procedure (e.g. balloon angioplasty) that alters or adjusts, or replaces a previously implanted PULSTA TPV during a 5-year follow-up period, and the frequency will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation</measure>
    <time_frame>5 years</time_frame>
    <description>Reoperation is defined as open surgery that alters or adjusts, or replaces a previously implanted PULSTA TPV during a 5-year follow-up period, and the frequency will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural / Device related serious adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (All cause / procedural/device-related)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Pulmonary Valve Regurgitation</condition>
  <condition>Pulmonary Valve Stenosis</condition>
  <condition>Tetralogy of Fallot</condition>
  <arm_group>
    <arm_group_label>PULSTA TPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PULSTA Transcatheter Pulmonary Valve (TPV) System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PULSTA TPV System</intervention_name>
    <description>PULSTA transcatheter pulmonary valve replacement.</description>
    <arm_group_label>PULSTA TPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight greater than or equal to 30 kilograms

          -  Pulmonary regurgitation moderate or severe pulmonary regurgitation or pulmonary valve
             stenosis with mean gradient &gt;35mmHg by echocardiography

          -  Main pulmonary artery trunk of ≥16 mm and ≤30 mm

          -  Patients willing to provide written informed consent and comply with follow-up
             evaluations.

        Exclusion Criteria:

          -  Females of child-bearing potential who are unable to take adequate contraceptive
             precautions, are known to be pregnant, or are currently breastfeeding an infant up
             until 6 months after TPV implantation

          -  Pre-existing mechanical valve in pulmonary position or require concomitant repair of
             other cardiac valves

          -  Obstruction of the central veins to be approached for the TPV implantation

          -  Coronary artery compression confirmed by angiography

          -  A known severe allergy to Nickel

          -  A known hypersensitivity to any anticoagulation therapy, contrast agent or a
             hemorrhagic disease

          -  Suspected active infectious disease (e.g. endocarditis, meningitis)

          -  Life expectancy of less than 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Carminati, PhD. MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinico San Donato</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Eicken, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Luis Zunzunegui, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gregorio Marañon hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federico Gutierrez Larraya, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ender Odemis, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Acibadem University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmet Çelebi, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Siyami Ersek Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregor Krings, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Utrecht University Wilhelmina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Krasemann, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gi Beom Kim, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Young Choi, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Ho Kim, PhD. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sejong Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jang Mi Ko</last_name>
    <phone>+82 31 904 6187</phone>
    <phone_ext>637</phone_ext>
    <email>jmko@stent.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munchen</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>Milan</city>
        <state>San Donato Milanese</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Haehak-ro Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Hohyun-ro, Sosa-gu</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yonsei-ro, Seodaemun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Wytemaweg</state>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Utrecht University Wilhelmina</name>
      <address>
        <city>Utrecht</city>
        <zip>3508</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gregorio Marañon hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem University Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Küçükçekmece/İstanbul</state>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siyami Ersek Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Üsküdar/İstanbul</state>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Pulmonary Valve Stenosis</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

